Foresite Capital

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company specializes in the development of a novel technology that allows for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. Evonetix aims to enhance DNA synthesis accuracy and scalability, making it accessible to researchers and transforming how DNA is produced and utilized for gene synthesis. With a highly experienced engineering team that combines expertise from various scientific and engineering disciplines, Evonetix is positioned to significantly impact the capabilities of synthetic biology by enabling applications that were previously unfeasible.

Nested Therapeutics is a stealth biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in the development of precision oncology therapies aimed at targeting specific cancer genes. By identifying new driver mutations, Nested Therapeutics employs a platform that integrates insights from genomics, computational chemistry, proteomics, and artificial intelligence to discover novel small-molecule drugs. This innovative approach enables healthcare professionals to administer more effective precision medications, ultimately improving treatment outcomes for cancer patients.

MyOme is a biotechnology company that specializes in gene analytics technology aimed at understanding the impact of DNA on health and well-being. Through advanced genome sequencing, MyOme provides insights into a range of common and rare diseases, including coronary heart disease. The company's innovative approach allows it to estimate the risk of various multi-factorial medical conditions, empowering families to take proactive measures to reduce the likelihood of diseases being inherited across generations. MyOme's data is designed to be secure, portable, and reusable throughout an individual's life, ensuring that valuable genetic information can be accessed and utilized effectively over time.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

Developer of transformative biotech company intended to create, annotate and biologically understand the world's most rigorous and extensive library of microproteins and produce entirely new, novel therapeutics. The company's technology identify novel, protein coding sequences hidden within the human genome, these small proteins mediate rich and diverse human biology, thereby harnessing the therapeutic potential of a novel class of human peptides.

Bit.bio is a synthetic biology company focused on revolutionizing the production and utilization of consistent and functional human cells. Their mission is to enhance health outcomes by applying computational principles to biological processes, specifically through their patented opti-ox™ technology. This innovative approach allows for the reprogramming of human induced pluripotent stem cells into precise and mature cell types. By providing scalable and reliable batches of human cells, Bit.bio aims to improve research, facilitate drug discovery, and foster the development of advanced cell and tissue therapies. The company has assembled a team of experts in stem cells, cellular reprogramming, and mathematical modeling, emphasizing collaboration and ambition to drive their goals forward. Through their efforts, Bit.bio seeks to democratize access to vital cellular resources, ultimately transforming the landscape of medicine.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Interline Therapeutics is a drug discovery company based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to address molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline has developed a precision medicine platform that focuses on three key areas: genomics, communities, and modulators. This approach enables the identification of new medicines targeting genetically validated signaling pathways, ensuring that drug candidates effectively correct dysfunctional disease networks. Through collaborations with leading academic groups, Interline aims to enhance its capabilities in drug discovery and development.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Interline Therapeutics is a drug discovery company based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to address molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline has developed a precision medicine platform that focuses on three key areas: genomics, communities, and modulators. This approach enables the identification of new medicines targeting genetically validated signaling pathways, ensuring that drug candidates effectively correct dysfunctional disease networks. Through collaborations with leading academic groups, Interline aims to enhance its capabilities in drug discovery and development.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

Sestina Bio, LLC, established in 2020 and headquartered in Delaware, is a biotechnology company dedicated to addressing global challenges through innovative synthetic biology solutions. The company's mission is to create an advanced research and development platform that integrates cutting-edge technologies such as synthetic biology, data sciences, and bio-analytical systems. Sestina Bio specializes in engineering yeast and bacteria to produce chemicals and pharmaceuticals using its proprietary genome editing tools, single-cell biology techniques, and machine learning algorithms.

Bit.bio is a synthetic biology company focused on revolutionizing the production and utilization of consistent and functional human cells. Their mission is to enhance health outcomes by applying computational principles to biological processes, specifically through their patented opti-ox™ technology. This innovative approach allows for the reprogramming of human induced pluripotent stem cells into precise and mature cell types. By providing scalable and reliable batches of human cells, Bit.bio aims to improve research, facilitate drug discovery, and foster the development of advanced cell and tissue therapies. The company has assembled a team of experts in stem cells, cellular reprogramming, and mathematical modeling, emphasizing collaboration and ambition to drive their goals forward. Through their efforts, Bit.bio seeks to democratize access to vital cellular resources, ultimately transforming the landscape of medicine.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company specializes in the development of a novel technology that allows for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. Evonetix aims to enhance DNA synthesis accuracy and scalability, making it accessible to researchers and transforming how DNA is produced and utilized for gene synthesis. With a highly experienced engineering team that combines expertise from various scientific and engineering disciplines, Evonetix is positioned to significantly impact the capabilities of synthetic biology by enabling applications that were previously unfeasible.

Generation Bio Co. is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies aimed at treating both rare and prevalent diseases. Founded in 2016 and formerly known as Torus Therapeutics, the company focuses on creating durable and redosable treatments for conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs a proprietary platform that utilizes closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP) to achieve targeted delivery of genetic materials across various tissues. This approach is designed to enhance treatment efficacy while expanding access to therapies for rare diseases and addressing more common conditions through scalable manufacturing processes.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Generation Bio Co. is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies aimed at treating both rare and prevalent diseases. Founded in 2016 and formerly known as Torus Therapeutics, the company focuses on creating durable and redosable treatments for conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs a proprietary platform that utilizes closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP) to achieve targeted delivery of genetic materials across various tissues. This approach is designed to enhance treatment efficacy while expanding access to therapies for rare diseases and addressing more common conditions through scalable manufacturing processes.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

AveXis, operating as Novartis Gene Therapies, Inc., is a biotechnology company focused on developing and commercializing gene therapies for rare and life-threatening neurological genetic diseases. Acquired by Novartis in 2018, the company specializes in innovative treatments such as motor neuron cell-targeted gene replacement therapy aimed at conditions like spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. These therapies are designed to assist healthcare institutions in addressing diseases that cause progressive muscle weakness, paralysis, and ultimately, death. Through its advancements in gene therapy, AveXis is dedicated to improving the lives of patients and families impacted by these severe genetic disorders.

Intellia Therapeutics, Inc. is a genome editing company headquartered in Cambridge, Massachusetts, specializing in the development of therapeutics using the CRISPR/Cas9 technology. This innovative platform allows for precise alterations of genomic DNA, enabling the company to pursue treatments for a range of severe and life-threatening diseases. Intellia's pipeline includes both in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as ex vivo programs focused on engineered cell therapies for oncological and autoimmune disorders. The company is also exploring treatments for conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Intellia has established collaborations with several organizations, enhancing its research and development capabilities. Founded in 2014, Intellia holds a significant intellectual property portfolio related to the therapeutic applications of CRISPR/Cas9, aiming to address high unmet medical needs through its advanced gene-editing approaches.

WaVe Life Sciences Ltd. is a clinical-stage genetic medicine company based in Singapore, focused on developing innovative treatments for genetically defined diseases using its proprietary PRISM platform. This platform enables the precise design, optimization, and production of stereopure oligonucleotides, which are designed to target genetic defects by either reducing harmful protein expression or converting dysfunctional proteins into functional ones. The company's primary focus is on neurology, particularly within the central and neuromuscular systems. WaVe Life Sciences collaborates with major pharmaceutical companies, including Pfizer and Takeda, to advance the research and development of its oligonucleotide therapeutics. Founded in 2012, the company aims to deliver transformative therapies to improve patient outcomes in both rare and prevalent disorders.

Sequenta is a biotechnology company focused on the development of clinical diagnostics that leverage innovative methods to assess immune system status. Founded in 2008 by previous entrepreneurs from ParaAllele BioScience, Sequenta employs advanced techniques to analyze the immune cell receptor genes, which exhibit significant variability in the human genome. This diversity is critical for understanding various health conditions and diseases, enabling Sequenta to provide insights that may influence numerous clinical decisions through a single, powerful assay. The company's approach capitalizes on the reduced costs of DNA sequencing, positioning Sequenta at the forefront of advancements in immune-related diagnostics.